
About LSL Pharma Group
LSL Pharma Group is a publicly listed company based in Boucherville (Canada) founded in 2023. Integrated pharmaceutical products are developed and supplied in Canada. LSL Pharma Group has completed 4 acquisitions, including Dermolabpharma, Du-Var and TargetCo. Its chief executive, as recorded, is Francois Roberge. LSL Pharma Group offers products and services including Pharmaceutical Products, Natural Health Products, and Cosmetics. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Drug Development. Its legal entity is Groupe LSL Pharma inc.
Company details
Groupe LSL Pharma was established in 2023 in Boucherville, Canada, as an integrated pharmaceutical entity. Focus is placed on life science innovations to address needs within the Canadian population. Operations encompass product development and distribution in the pharmaceutical sector. Recent developments include secured orders projected to generate over 2.6 million in annual revenue. Leadership is provided by CEO Francois Roberge.
- Headquarters Boucherville, Canada
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website groupelslpharma.com
- Social LinkedIn Facebook
- Legal Name Lsl Pharma Group Inc
- Annual Revenue$20.99 M (USD)61.96as on Dec 31, 2025
- Net Profit-$2.06 M (USD)-185.02as on Dec 31, 2025
- EBITDA$160.68 K (USD)-88.51as on Dec 31, 2025
- Latest Funding Round$1.65M (USD), Post-IPO
Sep 2025
- Investments & AcquisitionsDermolabpharma
& 3 more
Products & Services of LSL Pharma Group
LSL Pharma Group offers a comprehensive portfolio of products and services, including Pharmaceutical Products, Natural Health Products, and Cosmetics.
Manufacture sterile pharmaceuticals for health applications
Develop and distribute natural supplements for wellness
Formulate and produce cosmetic and pharmaceutical health items
Funding Insights of LSL Pharma Group
- Total Rounds 6
- Last Round Post-IPO β $1.65M
- First Round $2.45M
(Sep 2023)
All 6 funding rounds of LSL Pharma Group with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2025 | $1.65M | Post-IPO | β | β | β |
| Dec 2024 | Post-IPO | β | β | β | |
| Jul 2024 | $960,000 | Post-IPO | β | β | β |
| Jun 2024 | $1.09M | Post-IPO | β | β | β |
| Mar 2024 | $6.44M | Post-IPO | β | β | β |
| Sep 2023 | $2.45M | Post-IPO | β | β | β |
People of LSL Pharma Group
1 people are tracked at LSL Pharma Group (1 in leadership).
| Name | Role | Group |
|---|---|---|
Francois Roberge | CEO | Leadership |
Complete people profiles for LSL Pharma Group
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of LSL Pharma Group
LSL Pharma Group is a publicly listed company on the TSXV with ticker symbol LSL in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Mar 2023
- Listed onSZSE: LSL
- Listed entityLSL Pharma Group Inc
- Exchange sectorHealth technology
- ISINCA50190N1042
- Share price0.30 CAD (+1.69% on the day) · 2026-10-13
- Market capitalisation38,018,948.00 CAD
- Price to earnings15.3
- EPS (diluted, trailing year)-0.06 CAD
- Volume (last session)61,925
Financials of LSL Pharma Group
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 28.7M CAD | -2.8M CAD | 220,000 CAD |
| 2024 | 17.8M CAD | 3.3M CAD | 1.9M CAD |
| 2023 | 10.0M CAD | -8.5M CAD | -3.0M CAD |
| 2022 | -74,220 CAD | -70,850 CAD | |
| 2021 | -90,630 CAD | -87,520 CAD |
Detailed financial statements for LSL Pharma Group
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by LSL Pharma Group
LSL Pharma Group has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Dermolabpharma, Du-Var and TargetCo.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Skincare and cosmetic manufacturing services in Canada. | du-var.com | 0 | Jul 2025 | β’β’β’β’ | ||
Natural cosmetic, pharmaceutical, and health products are manufactured. | dermolabpharma.com | Sainte Julienne, Canada | 1985 | Dec 2024 | β’β’β’β’ | |
Natural supplements and healthcare products are provided for wellness. | viragesante.com | Levis, Canada | 1994 | Jun 2024 | β’β’β’β’ | |
Nutritional supplements are distributed by TargetCo to health-focused markets. | 0 | May 2024 | $2.5M |
Complete acquisition details for LSL Pharma Group
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of LSL Pharma Group
8 dated milestones of LSL Pharma Group across 2 years, from founding to its latest funding, stage changes and deals.
- Founded LSL Pharma Group is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $2.4M.
- Acquisition Acquires TargetCo.
- Acquisition Acquires Virage Sante.
- Acquisition Acquires Dermolabpharma.
- Acquisition Acquires Du-Var.
- Funding Latest funding round, Post-IPO, of $1.7M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lsl Pharma Group
Complete news archive for LSL Pharma Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LSL Pharma Group
LSL Pharma Group was founded in 2023.
LSL Pharma Group is headquartered in Boucherville, Canada. It is registered at Boucherville, Quebec, Canada.
Francois Roberge is the CEO of LSL Pharma Group, as recorded in our data.
Annual revenue of LSL Pharma Group is $20.99M as on Dec 31, 2025.
Groupe LSL Pharma was established in 2023 in Boucherville, Canada, as an integrated pharmaceutical entity. Focus is placed on life science innovations to address needs within the Canadian population. Operations encompass product development and distribution in the pharmaceutical sector. Recent developments include secured orders projected to generate over 2.6 million in annual revenue. Leadership is provided by CEO Francois Roberge.
LSL Pharma Group offers Pharmaceutical Products, Natural Health Products, and Cosmetics.
Yes, LSL Pharma Group is publicly traded on TSXV under the ticker symbol LSL.
LSL Pharma Group has made 4 acquisitions, including Dermolabpharma, Du-Var, and TargetCo.
LSL Pharma Group operates through Groupe Lsl Pharma Inc..
